報價延遲最少15分鐘:2025/07/20 16:04 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.78 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.07/-3.35
|
|
企業價值
769.18M
|
| 資產負債 |
|
每股賬面淨值
6.67
|
| 現金流量 |
|
現金流量率
0.09
|
| 損益表 |
|
收益
167.50M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/20 16:04 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. |
